BioSpace News Archive

BioCity Biopharma announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for a Phase 1 study of BC3448.

XNK Therapeutics AB announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer in San Diego in November.

Duality Biologics Co. Ltd. announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

Intensity Therapeutics, Inc. today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets. A conference call and webcast will follow at 8:00 am ET.

STAAR Surgical Company today announced that management will participate in several upcoming investor conferences.

Castle Biosciences, Inc. today announced a new study published in The American Journal of Gastroenterology showing how use of TissueCypher® Barrett’s Esophagus test results can significantly improve management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) to improve health outcomes.